TABLE 2.
A2780 |
H4 acetylation |
|||||||
---|---|---|---|---|---|---|---|---|
Belinostat, 100 mg/kg i.v. |
||||||||
ID | Pretreatment biopsy | 1 hbiopsy | 2 hbiopsy | 3 hbiopsy | 3 htumor | 6 hbiopsy | 6 htumor | 24 htumor |
Large tumors (1500–1800 mg) | ||||||||
235 | Weak | Strong | Weak | |||||
234 | Moderate | Strong | Moderate | |||||
226 | Weak | Strong | Weak | |||||
365 | Moderate | Strong | Moderate | |||||
232 | Weak | Strong | Moderate | |||||
233 | No | No | No | |||||
553 | – | Weak | Weak | |||||
Small tumors (300–400 mg) | ||||||||
227 | Strong | Weak | ||||||
238 | Strong | Moderate | ||||||
237 | Strong | Strong | ||||||
231 | Strong | – | ||||||
225 | Moderate | Moderate | ||||||
236 | Strong | Moderate | ||||||
228 | Strong | Weak | ||||||
230 | Weak | Weak | ||||||
552 | No |
Strong H4 acetylation is observed in biopsies collected 1 and 2 h after treatment. In most samples, acetylation is decreased after 3 h to a level similar to that observed in the pretreatment biopsies. Only weak acetylation is observed 6 h after treatment. (–, missing).